Back in the summer, I got the call that no biotech venture investor wants to get. On the morning of August 8th, I received an urgent text of “can you talk now?” quickly followed with a call. I learned then of very troubling news regarding a major preclinical safety concern, a “tox signal” in industry parlance, in one of our lead programs. Fast forward three months later, and we’re in the final steps of winding down the company. R.I.P. Quartet Medicine.
The field of gene and cell therapy has witnessed an unprecedented few months, almost unimaginable only a few years ago. It’s worth pausing to reflect on some of the recent highlights.
The term “undruggable” has entered common industry vernacular over the past two decades to describe biologic targets that couldn’t be addressed via narrow conventional pharmacologies involving catalytic-site inhibitors and antibodies.
Funding for biotech companies has been abundant this year. As covered the first week in October by Timmerman Report and Meg Tirrell on cnbc, biotech IPOs are pricing at a steady pace. Q3 2017 also saw the largest quarterly injection of VC funding into biopharma ever in the history of our industry, at $3.6B according to LifeSciVC.
This blog was written by Sam Truex, former CBO of Padlock and Synlogic, and current Atlas EIR, as part of the From the Trenches feature of LifeSciVC.
There’s a proverb that goes like this, “If you want to go fast, go alone; if you want to go far, go together; but if you want momentum, go with tailwinds.”
This blog was written by Jason Gardner, CEO and co-founder of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC.